Anil Shanker to Animals
This is a "connection" page, showing publications Anil Shanker has written about Animals.
Connection Strength
1.176
-
Renrick AN, Thounaojam MC, de Aquino MTP, Chaudhuri E, Pandhare J, Dash C, Shanker A. Bortezomib Sustains T Cell Function by Inducing miR-155-Mediated Downregulation of SOCS1 and SHIP1. Front Immunol. 2021; 12:607044.
Score: 0.062
-
Hodo TW, de Aquino MTP, Shimamoto A, Shanker A. Critical Neurotransmitters in the Neuroimmune Network. Front Immunol. 2020; 11:1869.
Score: 0.060
-
Srivastava RM, Marincola FM, Shanker A. Editorial: Lymphocyte Functional Crosstalk and Regulation. Front Immunol. 2019; 10:2916.
Score: 0.057
-
Renrick AN, Dunbar ZT, Shanker A. Update?on the current revolution in cancer immunotherapy. Immunotherapy. 2019 01; 11(1):15-20.
Score: 0.054
-
Shanker A, Thounaojam MC, Mishra MK, Dikov MM. Innate-Adaptive Immune Crosstalk 2016. J Immunol Res. 2017; 2017:3503207.
Score: 0.048
-
Pellom ST, Singhal A, Shanker A. Prospects of combining adoptive cell immunotherapy with bortezomib. Immunotherapy. 2017 03; 9(4):305-308.
Score: 0.047
-
Pellom ST, Dudimah DF, Thounaojam MC, Uzhachenko RV, Singhal A, Richmond A, Shanker A. Bortezomib augments lymphocyte stimulatory cytokine signaling in the tumor microenvironment to sustain CD8+T cell antitumor function. Oncotarget. 2017 Jan 31; 8(5):8604-8621.
Score: 0.047
-
Pulliam SR, Uzhachenko RV, Adunyah SE, Shanker A. Common gamma chain cytokines in combinatorial immune strategies against cancer. Immunol Lett. 2016 Jan; 169:61-72.
Score: 0.043
-
Shanker A, Thounaojam MC, Mishra MK, Dikov MM, Uzhachenko RV. Innate-Adaptive Immune Crosstalk. J Immunol Res. 2015; 2015:982465.
Score: 0.043
-
Shanker A, Pellom ST, Dudimah DF, Thounaojam MC, de Kluyver RL, Brooks AD, Yagita H, McVicar DW, Murphy WJ, Longo DL, Sayers TJ. Bortezomib Improves Adoptive T-cell Therapy by Sensitizing Cancer Cells to FasL Cytotoxicity. Cancer Res. 2015 Dec 15; 75(24):5260-72.
Score: 0.043
-
Thounaojam MC, Dudimah DF, Pellom ST, Uzhachenko RV, Carbone DP, Dikov MM, Shanker A. Bortezomib enhances expression of effector molecules in anti-tumor CD8+ T lymphocytes by promoting Notch-nuclear factor-?B crosstalk. Oncotarget. 2015 Oct 20; 6(32):32439-55.
Score: 0.043
-
Shanker A, Dikov MM, Carbone DP. Promise of Immunotherapy in Lung Cancer. Prog Tumor Res. 2015; 42:95-109.
Score: 0.043
-
Pellom ST, Dudimah DF, Thounaojam MC, Sayers TJ, Shanker A. Modulatory effects of bortezomib on host immune cell functions. Immunotherapy. 2015; 7(9):1011-22.
Score: 0.043
-
de Aquino MT, Malhotra A, Mishra MK, Shanker A. Challenges and future perspectives of T cell immunotherapy in cancer. Immunol Lett. 2015 Aug; 166(2):117-33.
Score: 0.042
-
Malhotra A, Shanker A. NK cells: immune cross-talk and therapeutic implications. Immunotherapy. 2011 Oct; 3(10):1143-66.
Score: 0.033
-
Shanker A, Marincola FM. Cooperativity of adaptive and innate immunity: implications for cancer therapy. Cancer Immunol Immunother. 2011 Aug; 60(8):1061-74.
Score: 0.032
-
Shanker A. Adaptive control of innate immunity. Immunol Lett. 2010 Jul 08; 131(2):107-12.
Score: 0.029
-
Shanker A, Buferne M, Schmitt-Verhulst AM. Cooperative action of CD8 T lymphocytes and natural killer cells controls tumour growth under conditions of restricted T-cell receptor diversity. Immunology. 2010 Jan; 129(1):41-54.
Score: 0.029
-
Shanker A, Brooks AD, Jacobsen KM, Wine JW, Wiltrout RH, Yagita H, Sayers TJ. Antigen presented by tumors in vivo determines the nature of CD8+ T-cell cytotoxicity. Cancer Res. 2009 Aug 15; 69(16):6615-23.
Score: 0.028
-
Shanker A, Brooks AD, Tristan CA, Wine JW, Elliott PJ, Yagita H, Takeda K, Smyth MJ, Murphy WJ, Sayers TJ. Treating metastatic solid tumors with bortezomib and a tumor necrosis factor-related apoptosis-inducing ligand receptor agonist antibody. J Natl Cancer Inst. 2008 May 07; 100(9):649-62.
Score: 0.026
-
Shanker A, Verdeil G, Buferne M, Inderberg-Suso EM, Puthier D, Joly F, Nguyen C, Leserman L, Auphan-Anezin N, Schmitt-Verhulst AM. CD8 T cell help for innate antitumor immunity. J Immunol. 2007 Nov 15; 179(10):6651-62.
Score: 0.025
-
Shanker A, Sayers T. Sensitizing tumor cells to immune-mediated cytotoxicity. Adv Exp Med Biol. 2007; 601:163-71.
Score: 0.023
-
Shanker A, Auphan-Anezin N, Chomez P, Giraudo L, Van den Eynde B, Schmitt-Verhulst AM. Thymocyte-intrinsic genetic factors influence CD8 T cell lineage commitment and affect selection of a tumor-reactive TCR. J Immunol. 2004 Apr 15; 172(8):5069-77.
Score: 0.019
-
Shanker A. Is thymus redundant after adulthood? Immunol Lett. 2004 Feb 15; 91(2-3):79-86.
Score: 0.019
-
Evans JV, Suman S, Goruganthu MUL, Tchekneva EE, Guan S, Arasada RR, Antonucci A, Piao L, Ilgisonis I, Bobko AA, Driesschaert B, Uzhachenko RV, Hoyd R, Samouilov A, Amann J, Wu R, Wei L, Pallerla A, Ryzhov SV, Feoktistov I, Park KP, Kikuchi T, Castro J, Ivanova AV, Kanagasabai T, Owen DH, Spakowicz DJ, Zweier JL, Carbone DP, Novitskiy SV, Khramtsov VV, Shanker A, Dikov MM. Improving combination therapies: targeting A2B-adenosine receptor to modulate metabolic tumor microenvironment and immunosuppression. J Natl Cancer Inst. 2023 11 08; 115(11):1404-1419.
Score: 0.019
-
Shanker A, Singh SM. Immunopotentiation in mice bearing a spontaneous transplantable T-cell lymphoma: role of thymic extract. Neoplasma. 2003; 50(4):272-9.
Score: 0.018
-
Tewary P, Brooks AD, Xu YM, Wijeratne EMK, Babyak AL, Back TC, Chari R, Evans CN, Henrich CJ, Meyer TJ, Edmondson EF, de Aquino MTP, Kanagasabai T, Shanker A, Gunatilaka AAL, Sayers TJ. Small-Molecule Natural Product Physachenolide C Potentiates Immunotherapy Efficacy by Targeting BET Proteins. Cancer Res. 2021 06 15; 81(12):3374-3386.
Score: 0.016
-
Shanker A, Singh SM, Sodhi A. Ascitic growth of a spontaneous transplantable T cell lymphoma induces thymic involution. 2. Induction of apoptosis in thymocytes. Tumour Biol. 2000 Nov-Dec; 21(6):315-27.
Score: 0.015
-
Shanker A, Singh SM, Sodhi A. Ascitic growth of a spontaneous transplantable T cell lymphoma induces thymic involution. 1. Alterations in the CD4/CD8 distribution in thymocytes. Tumour Biol. 2000 Sep-Oct; 21(5):288-98.
Score: 0.015
-
Goruganthu MUL, Shanker A, Dikov MM, Carbone DP. Specific Targeting of Notch Ligand-Receptor Interactions to Modulate Immune Responses: A Review of Clinical and Preclinical Findings. Front Immunol. 2020; 11:1958.
Score: 0.015
-
Shanker A, Singh SM, Sodhi A. Impairment of T-cell functions with the progressive ascitic growth of a transplantable T-cell lymphoma of spontaneous origin. FEMS Immunol Med Microbiol. 2000 Mar; 27(3):247-55.
Score: 0.015
-
Shanker A, Singh SM. Characterization of factors inducing apoptosis in thymocytes of mice bearing a transplantable T-cell lymphoma of spontaneous origin. Neoplasma. 2000; 47(2):90-5.
Score: 0.014
-
Tchekneva EE, Goruganthu MUL, Uzhachenko RV, Thomas PL, Antonucci A, Chekneva I, Koenig M, Piao L, Akhter A, de Aquino MTP, Ranganathan P, Long N, Magliery T, Valujskikh A, Evans JV, Arasada RR, Massion PP, Carbone DP, Shanker A, Dikov MM. Determinant roles of dendritic cell-expressed Notch Delta-like and Jagged ligands on anti-tumor T?cell immunity. J Immunother Cancer. 2019 04 02; 7(1):95.
Score: 0.014
-
Uzhachenko R, Boyd K, Olivares-Villagomez D, Zhu Y, Goodwin JS, Rana T, Shanker A, Tan WJ, Bondar T, Medzhitov R, Ivanova AV. Mitochondrial protein Fus1/Tusc2 in premature aging and age-related pathologies: critical roles of calcium and energy homeostasis. Aging (Albany NY). 2017 03 26; 9(3):627-649.
Score: 0.012
-
Uzhachenko R, Shanker A, Dupont G. Computational properties of mitochondria in T cell activation and fate. Open Biol. 2016 11; 6(11).
Score: 0.012
-
Lawrence S, Pellom ST, Shanker A, Whalen MM. Tributyltin exposure alters cytokine levels in mouse serum. J Immunotoxicol. 2016 11; 13(6):870-878.
Score: 0.011
-
Biktasova AK, Dudimah DF, Uzhachenko RV, Park K, Akhter A, Arasada RR, Evans JV, Novitskiy SV, Tchekneva EE, Carbone DP, Shanker A, Dikov MM. Multivalent Forms of the Notch Ligand DLL-1 Enhance Antitumor T-cell Immunity in Lung Cancer and Improve Efficacy of EGFR-Targeted Therapy. Cancer Res. 2015 Nov 15; 75(22):4728-41.
Score: 0.011
-
Uzhachenko R, Shanker A, Yarbrough WG, Ivanova AV. Mitochondria, calcium, and tumor suppressor Fus1: At the crossroad of cancer, inflammation, and autoimmunity. Oncotarget. 2015 Aug 28; 6(25):20754-72.
Score: 0.011
-
Uzhachenko R, Ivanov SV, Yarbrough WG, Shanker A, Medzhitov R, Ivanova AV. Fus1/Tusc2 is a novel regulator of mitochondrial calcium handling, Ca2+-coupled mitochondrial processes, and Ca2+-dependent NFAT and NF-?B pathways in CD4+ T cells. Antioxid Redox Signal. 2014 Apr 01; 20(10):1533-47.
Score: 0.010
-
Huang Y, Lin L, Shanker A, Malhotra A, Yang L, Dikov MM, Carbone DP. Resuscitating cancer immunosurveillance: selective stimulation of DLL1-Notch signaling in T cells rescues T-cell function and inhibits tumor growth. Cancer Res. 2011 Oct 01; 71(19):6122-31.
Score: 0.008
-
Hallett WH, Ames E, Motarjemi M, Barao I, Shanker A, Tamang DL, Sayers TJ, Hudig D, Murphy WJ. Sensitization of tumor cells to NK cell-mediated killing by proteasome inhibition. J Immunol. 2008 Jan 01; 180(1):163-70.
Score: 0.006
-
Abdool K, Cretney E, Brooks AD, Kelly JM, Swann J, Shanker A, Bere EW, Yokoyama WM, Ortaldo JR, Smyth MJ, Sayers TJ. NK cells use NKG2D to recognize a mouse renal cancer (Renca), yet require intercellular adhesion molecule-1 expression on the tumor cells for optimal perforin-dependent effector function. J Immunol. 2006 Aug 15; 177(4):2575-83.
Score: 0.006
-
Cretney E, Shanker A, Yagita H, Smyth MJ, Sayers TJ. TNF-related apoptosis-inducing ligand as a therapeutic agent in autoimmunity and cancer. Immunol Cell Biol. 2006 Feb; 84(1):87-98.
Score: 0.005
-
Roy R, Singh SM, Shanker A, Sodhi A. Mechanism of thymocyte apoptosis induced by serum of tumor-bearing host: the molecular events involved and their inhibition by thymosin alpha-1. Int J Immunopharmacol. 2000 Apr; 22(4):309-21.
Score: 0.004